Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
- PMID: 10371176
- DOI: 10.1097/00002030-199905280-00011
Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
Abstract
Objective: HIV-induced CD4 lymphocyte depletion is partially reversed by antiretroviral therapy but it is unclear if the degree to which the CD4 count rises depends on viral suppression (if so, the extent of viral suppression required to achieve a maximal CD4 count rise), whether the rise is sustainable and whether it occurs in patients with CD4 count <10 x 10(6) cells/l. We aimed to address these issues.
Methods: We studied CD4 count and plasma HIV RNA values every 4 weeks for 72 weeks in 154 patients starting indinavir-containing regimens.
Results: Mean baseline HIV RNA and CD4 count were 4.8 log10 copies/ml and 180 x 10(6) cells/l, respectively. Overall, there was a mean increase in CD4 count of 143 x 10(6) cells/l by 72 weeks. The adjusted mean increase (adjusted for initial viral load, CD4 count and age) was strongly related to the mean viral suppression over the follow-up period (P < 0.0001). Importantly, there was a highly significant difference (P = 0.0004) in the rise in CD4 count between those with 2-3 log suppression (161 x 10(6) cells/l) and those with > 3 log suppression (314 x 10(6) cells/l; mean 3.6 log suppression in this group), suggesting that with even greater suppression the rise in CD4 lymphocytes may be still larger. We also studied whether CD4 counts were still rising after 72 weeks in patients with sustained suppression of at least 3 log in viral load. There was a significant (P = 0.004; paired t-test) rise in count of 43 x 10(6) cells/l between weeks 64 and 72 in these patients, suggesting that regeneration continues at least up to 72 weeks after therapy, provided virus replication continues to be suppressed. Patients with initial CD4 counts < 10 x 10(6) cells/l experienced no smaller rises than those at higher levels, even after adjustment for other factors.
Conclusion: These results strongly support a direct causal relationship between HIV replication and CD4 lymphocyte count depletion. The rise in those with > 3 log suppression provides the best available indicator of the potential for natural CD4 regeneration in HIV-infected patients. However, since still greater CD4 count rises may be seen with more suppressive regimens, it may not be possible to study the intrinsic CD4 regenerative capacity until such regimens are available.
Similar articles
-
Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.AIDS. 1998 Jul 30;12(11):1333-40. doi: 10.1097/00002030-199811000-00015. AIDS. 1998. PMID: 9708413
-
Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).AIDS. 1999 May 7;13(7):F53-8. doi: 10.1097/00002030-199905070-00001. AIDS. 1999. PMID: 10357371 Clinical Trial.
-
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.Ann Intern Med. 2001 Dec 4;135(11):954-64. doi: 10.7326/0003-4819-135-11-200112040-00007. Ann Intern Med. 2001. PMID: 11730396 Clinical Trial.
-
Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report.Ann Intern Med. 2000 Sep 19;133(6):435-8. doi: 10.7326/0003-4819-133-6-200009190-00011. Ann Intern Med. 2000. PMID: 10975961 Review.
-
Special considerations regarding antiretroviral therapy and infection prophylaxis in the HIV-infected individual with cancer.Cancer Treat Res. 2001;104:347-66. doi: 10.1007/978-1-4615-1601-9_14. Cancer Treat Res. 2001. PMID: 11191134 Review. No abstract available.
Cited by
-
Among patients with sustained viral suppression in a resource-limited setting, CD4 gains are continuous although gender-based differences occur.PLoS One. 2013 Aug 27;8(8):e73190. doi: 10.1371/journal.pone.0073190. eCollection 2013. PLoS One. 2013. PMID: 24013838 Free PMC article. Clinical Trial.
-
Thymic function and T cell parameters in a natural human experimental model of seasonal infectious diseases and nutritional burden.J Biomed Sci. 2011 Jun 15;18(1):41. doi: 10.1186/1423-0127-18-41. J Biomed Sci. 2011. PMID: 21676219 Free PMC article.
-
Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe.PLoS One. 2014 Jan 31;9(1):e87160. doi: 10.1371/journal.pone.0087160. eCollection 2014. PLoS One. 2014. PMID: 24498036 Free PMC article.
-
The immunological response of HIV-positive patients initiating HAART at the Komfo Anokye Teaching Hospital, Kumasi, Ghana.Ghana Med J. 2013 Dec;47(4):164-70. Ghana Med J. 2013. PMID: 24669021 Free PMC article.
-
Histological effects of chronic administration of efavirenz on lateral geniculate body of adult Wistar rats.N Am J Med Sci. 2010 Jan;2(1):1-4. doi: 10.4297/najms.2010.11. N Am J Med Sci. 2010. PMID: 22624105 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials